Status:

UNKNOWN

CALM-AD

Lead Sponsor:

Institute of Psychiatry, London

Collaborating Sponsors:

Medical Research Council

Alzheimer's Society

Conditions:

Alzheimer's Disease

Eligibility:

All Genders

40+ years

Phase:

PHASE4

Brief Summary

Primary Aim To determine whether; * Donepezil is significantly better than placebo in the management of agitation in Alzheimer's Disease that has not responded to, or is inappropriate for a standard...

Eligibility Criteria

Inclusion

  • a diagnosis of dementia consistent with Diagnostic and Statistical Manual of Mental Health Disorders, revised 3rd edition (DSM-III-R) (APA, 1987) National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) diagnostic criteria for probably or possible AD (MKhann et al, 1984) (Appendix 6) clinically significant agitation (defined as causing distress to patient and at least moderate management problems for carers on at least two days per week for a two week period, together with a Cohen Mansfield Agitation Inventory (CMAI) (Cohen-Mansfield, 1986) (Appendix 11 A) score \>39 age \>39 years resident in care facility or community living with a carer not receiving treatment with neuroleptics or cholinesterase inhibitors currently or in the past four weeks and responsible clinician not considering treatment with cholinesterase inhibitor for the next 16 weeks taking into account the clinical evidence base and NICE guideline (NICE, 2001) patient with capacity willing to consent to study or will to participate in study if lacking capacity carer with capacity willing to consent to study and in agreement for patient lacking capacity to participate if patient willing to participate
  • \-

Exclusion

  • known sensitivity to Donepezil severe, unstable or uncontrolled medical conditions apparent from history, physical examination or investigations current evidence of delirium patient meets criteria for Probably Dementia with Lewy Bodies (McKeith et al, 1996) low probability of treatment compliance
  • \-

Key Trial Info

Start Date :

November 1 2003

Trial Type :

INTERVENTIONAL

End Date :

December 1 2005

Estimated Enrollment :

190 Patients enrolled

Trial Details

Trial ID

NCT00142324

Start Date

November 1 2003

End Date

December 1 2005

Last Update

December 14 2005

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Queen Elizabeth Psychiatric Hospital

Birmingham, United Kingdom, B15 2QZ

2

Department of Psychiatry for the Elderly, Leicester General Hospital

Leicester, United Kingdom, LE5 4PW

3

Institute of Psychiatry, King's College, London

London, United Kingdom, SE5 8AF

4

Old Age Psychiatry, Wythenshawe Hospital, Manchester

Manchester, United Kingdom, M23 9LT